Our laboratory is strongly focused on dissecting the transcriptional landscape of the intestinal mucosa in patients with ulcerative colitis and Crohn’s disease. Genome-wide transcriptional profiling has become a key approach to uncover disease-driving mechanisms and to define molecular signatures associated with response or resistance to current therapies.
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases (IBD) that cause progressive tissue damage and long-term disability. Although therapeutic options have expanded in recent years, a substantial proportion of patients fail to respond or lose response over time. Single-cell RNA sequencing (scRNA-seq) enables high-resolution characterization of disease-associated cell states and pathways, providing insights into mechanisms that may sustain inflammation and drive therapeutic refractoriness.
Spatial transcriptomics complements single-cell approaches by preserving the architectural context of the tissue. By mapping gene expression directly within intestinal sections, this technology reveals how inflammatory programs, immune infiltration, and epithelial remodeling are organized across distinct mucosal regions. In IBD, spatial transcriptomics offers a unique opportunity to identify localized pathogenic niches and tissue-specific transcriptional programs that may underlie disease persistence and variable therapeutic response.
Thanks for your visit. Copyright © 2022 IBD Lab. All rights reserved.